| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.JHIN.2003.08.012 |
| P698 | PubMed publication ID | 14572481 |
| P2093 | author name string | Hobson RP | |
| P433 | issue | 3 | |
| P921 | main subject | epidemiology | Q133805 |
| P304 | page(s) | 159-68; quiz 233 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Journal of Hospital Infection | Q15746468 |
| P1476 | title | The global epidemiology of invasive Candida infections--is the tide turning? | |
| P478 | volume | 55 |
| Q51185547 | Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. |
| Q41518398 | Alterations of serum cytokine levels and their relation with inflammatory markers in candidemia. |
| Q39358570 | Antifungal effect of 4-arylthiosemicarbazides against Candida species. Search for molecular basis of antifungal activity of thiosemicarbazide derivatives. |
| Q36958193 | Binding Sites in the EFG1 Promoter for Transcription Factors in a Proposed Regulatory Network: A Functional Analysis in the White and Opaque Phases of Candida albicans |
| Q37392907 | Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates |
| Q44632517 | Bloodstream yeast infections in a university hospital in Northeast Turkey: a 4-year survey |
| Q34719843 | Candida guilliermondii fungemia in patients with hematologic malignancies |
| Q37613000 | Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility |
| Q43612565 | Candida species distribution in bloodstream cultures in Lyon, France, 1998-2001. |
| Q33927464 | Candidacidal activity of synthetic peptides based on the antimicrobial domain of the neutrophil-derived protein, CAP37 |
| Q42375493 | Candidaemia in a tertiary hospital in Nigeria |
| Q46874313 | Development of multiplex loop-mediated isothermal amplification assays to detect medically important yeasts in dairy products |
| Q36623050 | Developments in the treatment of candidiasis: more choices and new challenges |
| Q42589056 | Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1. |
| Q24645700 | Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis |
| Q34019188 | Echinocandins: the newest class of antifungals |
| Q33770019 | Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits |
| Q41855759 | Efficient identification of clinically relevant Candida yeast species by use of an assay combining panfungal loop-mediated isothermal DNA amplification with hybridization to species-specific oligonucleotide probes |
| Q35199322 | Emergence of nonalbicans Candida in neonatal septicemia and antifungal susceptibility: experience from a tertiary care center |
| Q24562996 | Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs |
| Q64948530 | Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network. |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q28834232 | Evaluation of Fluorescent Capillary Electrophoresis for Rapid Identification of Candida Fungal Infections |
| Q41868883 | Evaluation of blood culture media for the detection of fungi. |
| Q37159784 | Expression of mouse beta defensin 2 in escherichia coli and its broad-spectrum antimicrobial activity |
| Q36286490 | Global trends in candidemia: review of reports from 1995-2005. |
| Q42271039 | Identification and functional characterization of Rca1, a transcription factor involved in both antifungal susceptibility and host response in Candida albicans |
| Q46784358 | International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. |
| Q47145124 | Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA - Opinion of the Scientific Committee |
| Q40415922 | Local, systemic, demographic, and health-related factors influencing pathogenic yeast spectrum and antifungal drug administration frequency in oral candidiasis: a retrospective study |
| Q35904821 | Management of invasive candidiasis in critically ill patients |
| Q35437454 | N-Cyclo-propyl-N-[2-(2,4-difluoro-phen-yl)-2-hy-droxy-1-(1H-1,2,4-triazol-1-yl)prop-yl]-2-(5-methyl-2,4-dioxo-1,2,3,4-tetra-hydro-pyrimidin-1-yl)acetamide dichloro-methane 0.62-solvate |
| Q33515689 | Performance of optimized McRAPD in identification of 9 yeast species frequently isolated from patient samples: potential for automation |
| Q44217079 | Risk factors for candidaemia in critically ill patients: a prospective surveillance study |
| Q38787319 | Sedaxicenes: potential new antifungal ferrocene-based agents? |
| Q34578357 | Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates. |
| Q40486070 | Susceptibility to antifungal agents and enzymatic activity of Candida haemulonii and Cutaneotrichosporon dermatis isolated from soft corals on the Brazilian reefs. |
| Q64236059 | The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses? |
| Q36742397 | The echinocandins |
| Q47146151 | The maintenance of the list of QPS microorganisms intentionally added to food or feed - Scientific Opinion of the Panel on Biological Hazards |
| Q38984025 | Topographical and physiological differences of the skin mycobiome in health and disease |
| Q39026377 | Vitamin D and Infectious Diseases: Simple Bystander or Contributing Factor? |
| Q37157325 | ZCF32, a fungus specific Zn(II)2 Cys6 transcription factor, is a repressor of the biofilm development in the human pathogen Candida albicans |
Search more.